• About us
• Contact

Advertisement

Organisation › Details

Pelago Bioscience AB

Spun out from the Karolinska Institute, Stockholm Sweden, Pelago Bioscience AB was founded in 2013 to provide and develop the patented Cellular Thermal Shift Assay (CETSA™) for use in determination and quantification of drug–target interactions. Pelago Bioscience has during the first two operational years delivered in situ target engagement studies to more than a dozen pharmaceutical companies to accelerate their preclinical and clinical drug discovery projects. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects. This reduces time and money spent on the non-optimal compounds and allows faster development of more efficacious new drugs. *

 

	Start	2013-01-01 splitoff
	Predecessor	Karolinska Institutet
	Industry	contract research (drugs)
	Industry 2	Cellular Thermal Shift Assay (CETSA™ method)
	Person	Dabrowski, Michael (Pelago Bioscience AB 201506 CEO)
	Street	20 Banvaktsvägen
	City	17148 Solna
		Address record changed: 2020-12-02
Basic data	Employees	A: 1 to 10 (2014-11-08)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.